OptiNose, Inc. (OPTN)

0.9277 -0.0923 (-9.05%) At close: 04:00PM EDT

OptiNose, Inc.

1020 Stony Hill Road
Suite 300
Yardley, PA 19067
United States
267 364 3500
https://www.optinose.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 132

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ramy A. Mahmoud M.D., M.P.H.	CEO & Director	731.59k	N/A	1965
Mr. Michael F. Marino Esq.	Chief Legal Officer & Corporate Secretary	604.24k	N/A	1976
Mr. Anthony J. Krick	Vice President & Chief Accounting Officer	N/A	N/A	1981
Mr. Jonathan Neely	Vice President of Investor Relations & Business Operations	N/A	N/A	N/A
Ms. Karen E. Brophy	Chief Human Resources Officer & VP of Human Resources	N/A	N/A	1963
Mr. Paul Spence	Chief Commercial Officer	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Corporate governance

OptiNose, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.